Join us on Thursday, 30th January for an exclusive 45-minute masterclass on microbial fermentation, led by experts from Olon and GTP Bioways.

Microbial fermentation is a foundational technology in biopharma manufacturing, underpinning the production of biologics, vaccines, antibiotics, and producing key small molecules like antibiotics and amino acids.

The Masterclass will give you an overview of  Microbial Fermentation, and how you can go from an early stage to full commercial manufacturing.

• Market Trends & Importance: Understand the strategic growth in microbial fermentation and the rising demand for biologics, vaccines, and small molecules that rely on this technology
• Early Stage Best Practices: Learn how to overcome common roadblocks biotechs, based on GTP Bioway’s extensive experience in early-stage microbial fermentation development 
• Commercial Stage Best Practices: Learn how to scale and producing consistent, high-quality microbial-based product, based on Olon Group’s experience in commercial manufacturing. 
• Real-World Case Studies: Get a behind-the-scenes look at how to successfully execute microbial fermentation projects and achieve key metrics with seamless development

This Masterclass is a must-attend for biopharma professionals seeking to elevate their approach to microbial fermentation and leverage expert insights for successful development and manufacturing projects.

Expert speakers

Hervé Ginisty, CSO, GTP Bioways

Following a PhD focused on protein-RNA interactions and ribosome biogenesis, Hervé spent two years as a Postdoctoral Researcher in human genetics before joining GTP Technology (now GTP Bioways) as Chief Scientific Officer. For the past 22 years, he has been deeply involved in designing and optimizing solutions for the expression and purification of recombinant proteins in both mammalian and microbial hosts. He has participated in the development of dozens of processes for a variety of biotherapeutics, including monoclonal antibodies and challenging proteins.

Andrea Conforto, Vice President CDMO Biotech, Olon SpA

Andrea Conforto, after earning his Master’s degree in Chemistry from the “Università degli Studi di Napoli – Federico II” in Italy, obtained his PhD in Environmental Science in 2007 from the “Seconda Università degli Studi di Napoli – SUN” in Caserta, Italy. During his PhD, completed in collaboration with the Dutch multinational Royal DSM (now DSM-Firmenich), he began working as a Process Engineer for the production of Active Pharmaceutical Ingredients (API) and food ingredients at the DSM Capua production site in Italy.

Following his PhD, he spent another seven years at DSM, working at both the Capua site and the Delft Biotech Center in Delft, the Netherlands, in various positions within the microbial fermentation field, including Project Manager for Tech Transfer, Costing Manager, and Project Director.

After his time at DSM, he transitioned to the business side of microbial fermentation CDMO, working as an Account Manager for Patheon, as Business Development Manager for Capua BioServices spa, and currently, as Vice President of the CDMO Biotech division at Olon spa.

In this role, he oversees business development, account management, business intelligence, and marketing activities for the CDMO biotech division, serving both the pharmaceutical and food industries. He collaborates with large corporations and start-ups to support technology transfer, process development, and manufacturing for new API and new ingredients for the food and infant food markets using precision fermentation.

Gerald Hofmann, Technology Development Manager at Olon SpA

Gerald received is Master of Science from the Technical University of Vienna followed by a PhD in Biotechnology from the Technical University of Denmark by doing research on filamentous fungi. His first exposure to applied industrial biotechnology was as Process Engineer for the optimization of fermentation processes at Novozymes (now Novonesis), after which he joined the Capua site (Italy) of DSM (now DSM-Firmenich).

Throughout the transition of the Capua site from DSM to Patheon, then to Capua Bioservices, and finally Olon, he has been responsible now for more than 10 years for the implementation of new products and processes as the head of the Technology Development Department that manages projects for process development as well as technology transfers.